JP6193981B2 - 哺乳動物における骨量減少を予防する乳酸菌の選択及び使用 - Google Patents

哺乳動物における骨量減少を予防する乳酸菌の選択及び使用 Download PDF

Info

Publication number
JP6193981B2
JP6193981B2 JP2015515983A JP2015515983A JP6193981B2 JP 6193981 B2 JP6193981 B2 JP 6193981B2 JP 2015515983 A JP2015515983 A JP 2015515983A JP 2015515983 A JP2015515983 A JP 2015515983A JP 6193981 B2 JP6193981 B2 JP 6193981B2
Authority
JP
Japan
Prior art keywords
lactobacillus reuteri
bone
base pair
lactic acid
bone loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015515983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526389A5 (enExample
JP2015526389A (ja
Inventor
コノリー、イーモン
ザ セカンド、ロバート アレン ブリトン
ザ セカンド、ロバート アレン ブリトン
レイ マッケイブ、ローラ
レイ マッケイブ、ローラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia AB
Original Assignee
Biogaia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB filed Critical Biogaia AB
Publication of JP2015526389A publication Critical patent/JP2015526389A/ja
Publication of JP2015526389A5 publication Critical patent/JP2015526389A5/ja
Application granted granted Critical
Publication of JP6193981B2 publication Critical patent/JP6193981B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015515983A 2012-06-04 2013-06-04 哺乳動物における骨量減少を予防する乳酸菌の選択及び使用 Active JP6193981B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261689338P 2012-06-04 2012-06-04
US61/689,338 2012-06-04
PCT/SE2013/050646 WO2013184064A1 (en) 2012-06-04 2013-06-04 Selection and use of lactic acid bacteria preventing bone loss in mammals

Publications (3)

Publication Number Publication Date
JP2015526389A JP2015526389A (ja) 2015-09-10
JP2015526389A5 JP2015526389A5 (enExample) 2016-07-14
JP6193981B2 true JP6193981B2 (ja) 2017-09-06

Family

ID=49712339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515983A Active JP6193981B2 (ja) 2012-06-04 2013-06-04 哺乳動物における骨量減少を予防する乳酸菌の選択及び使用

Country Status (16)

Country Link
US (4) US20150150917A1 (enExample)
EP (2) EP2854826B9 (enExample)
JP (1) JP6193981B2 (enExample)
KR (2) KR102191537B1 (enExample)
CN (1) CN104755091B (enExample)
AU (2) AU2013272330B2 (enExample)
CA (1) CA2875841C (enExample)
DK (2) DK3456334T3 (enExample)
ES (2) ES2847424T3 (enExample)
HR (1) HRP20190162T1 (enExample)
HU (1) HUE042643T2 (enExample)
LT (1) LT2854826T (enExample)
PL (2) PL2854826T3 (enExample)
SI (1) SI2854826T1 (enExample)
TR (1) TR201901771T4 (enExample)
WO (1) WO2013184064A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101915904B1 (ko) 2016-08-12 2018-11-06 한국식품연구원 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물
KR102120479B1 (ko) * 2018-10-30 2020-06-09 주식회사 종근당바이오 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
US12427174B2 (en) * 2019-02-05 2025-09-30 Biomedit, Inc. Probiotic compositions comprising lactobacillus reuteri strains and methods of use
KR102080498B1 (ko) * 2019-08-23 2020-02-24 정영옥 페룰산 및 유산균을 유효성분으로 포함하는 골감소증 개선 또는 예방용 식품 조성물
JP7596301B2 (ja) * 2019-12-02 2024-12-09 雪印メグミルク株式会社 骨強化剤
CN111718903A (zh) * 2020-06-24 2020-09-29 江南大学 一种筛选可预防和/或治疗骨质疏松的药物的方法
CN114711429B (zh) * 2021-06-08 2023-11-17 青岛蔚蓝生物股份有限公司 一株具有增强骨健康作用的罗伊氏乳杆菌及其应用
CN114634901B (zh) * 2022-05-18 2022-08-30 微康益生菌(苏州)股份有限公司 一种促进骨骼健康的干酪乳杆菌lc16及其培养方法与应用
KR102937770B1 (ko) * 2023-08-09 2026-03-12 국립한국교통대학교산학협력단 골다공증 억제 균주 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1511502A2 (en) * 2002-06-13 2005-03-09 Alimentary Health Limited Probiotic therapies using lactobacillus reuteri
US7344867B2 (en) * 2005-04-15 2008-03-18 Eamonn Connolly Selection and use of lactic acid bacteria for reducing inflammation in mammals
EP1918373B1 (en) * 2005-07-26 2014-08-20 Nestec S.A. Anti-obesity agent and anti-obesity food
WO2008028300A1 (en) * 2006-09-07 2008-03-13 Mcgill University Oral polymeric membrane feruloyl esterase producing bacteria formulation
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis

Also Published As

Publication number Publication date
KR20150028968A (ko) 2015-03-17
EP2854826A1 (en) 2015-04-08
HRP20190162T1 (hr) 2019-04-05
HUE042643T2 (hu) 2019-07-29
KR20200044134A (ko) 2020-04-28
US20180200313A1 (en) 2018-07-19
US9968643B2 (en) 2018-05-15
EP2854826B9 (en) 2019-05-08
CN104755091A (zh) 2015-07-01
ES2711427T3 (es) 2019-05-03
EP2854826B1 (en) 2018-11-14
AU2013272330B2 (en) 2017-11-02
PL2854826T3 (pl) 2019-06-28
EP2854826A4 (en) 2016-07-06
AU2013272330A1 (en) 2015-01-15
DK2854826T3 (en) 2019-03-11
AU2018200524B2 (en) 2019-07-18
SI2854826T1 (sl) 2019-03-29
US20150150917A1 (en) 2015-06-04
CA2875841C (en) 2021-02-02
JP2015526389A (ja) 2015-09-10
PL3456334T3 (pl) 2021-05-04
HK1211847A1 (en) 2016-06-03
EP3456334A1 (en) 2019-03-20
CA2875841A1 (en) 2013-12-12
AU2018200524A1 (en) 2018-02-15
US10232001B2 (en) 2019-03-19
CN104755091B (zh) 2020-07-21
US10537598B2 (en) 2020-01-21
LT2854826T (lt) 2019-02-11
ES2711427T8 (es) 2019-06-20
DK3456334T3 (da) 2021-01-25
TR201901771T4 (tr) 2019-03-21
WO2013184064A1 (en) 2013-12-12
KR102191537B1 (ko) 2020-12-16
ES2847424T3 (es) 2021-08-03
US20170128501A1 (en) 2017-05-11
US20190142879A1 (en) 2019-05-16
EP3456334B1 (en) 2020-11-11

Similar Documents

Publication Publication Date Title
US10537598B2 (en) Selection and use of lactic acid bacteria preventing bone loss in mammals
Kim et al. Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice
TWI604052B (zh) 促進骨質再生的植物乳桿菌菌株ｇｍｎｌ－６６２及其組合物
CN113382740A (zh) 包含细菌菌株的组合物
EP4670789A2 (en) MICROBIAL COMPOSITIONS AND PRODUCTION PROCESSES FOR IMPROVED PROBIOTIC ASSEMBLIES
AU2016344770A1 (en) Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
CN108567800A (zh) 副干酪乳杆菌菌株gmnl-653用于制备抗骨质流失的组合物的用途
JP2021519763A (ja) 炎症性腸疾患を治療するための組成物及び方法
CN108624520A (zh) 促进骨质再生的植物乳杆菌菌株gmnl-662及其组合物
Liu et al. The effects of Bacillus subtilis QST713 and β-mannanase on growth performance, intestinal barrier function, and the gut microbiota in weaned piglets
Luise et al. Blend of natural and natural identical essential oil compounds as a strategy to improve the gut health of weaning pigs
JP2020143020A (ja) エガセラ属細菌の菌数抑制剤
JP6716330B2 (ja) ウロプラキン発現促進剤
KR20210142692A (ko) 칼슘의 흡수를 촉진하는 신규 락트산 박테리아 균주 - 펩티드 및 연관 생성물
TWI607759B (zh) 副乾酪乳桿菌菌株ｇｍｎｌ－６５３用於製備抗骨質流失的組合物的用途
TWI740101B (zh) 降膽固醇之益生菌株的用途
HK1211847B (en) Selection and use of lactic acid bacteria preventing bone loss in mammals
TW202440136A (zh) 鼠李糖乳桿菌之核苷酸用於製備抗脂肪生成之組合物的用途
Class et al. Patent application title: Use of Bifidobacterium Animalis for Treating or Preventing Body Weight Gain and Insulin Resistance Inventors: Jian Shen (Shanghai, CN) Jingjing Wang (Shanghai, CN) Liping Zhao (Shanghai, CN) Martin Saul Obin (West Newton, MA, US) Muriel Derrien (Bures Sur Yvette, FR) Emilie Rocher (Massy, FR) Johan Van Hylckama Vlieg (Marly Le Roi, FR) Assignees: TUFTS UNIVERSITY COMPAGNIE GERVAIS DANONE
Wang et al. 922 Angiotensin Converting Enzyme Modulates Epithelial Cell Apoptosis in a Massive Intestinal Resection Rat Model: Role of At1r Receptor
Barnes et al. 923 The Addition of Synbiotics to Partial Enteral Nutrition Enhances Intestinal Adaptation in a Piglet Model of Intestinal Failure
Ramadass 924 Glutamine Attenuates the Toxic Effects of Legumes via Stimulation of HSP Production

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170810

R150 Certificate of patent or registration of utility model

Ref document number: 6193981

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250